Publications by authors named "Gina Eriksson"
Article Synopsis
- The study aimed to evaluate the safety and effectiveness of belimumab in older adults (65+) with systemic lupus erythematosus (SLE) by analyzing data from several clinical trials.
- While older adults showed lower disease activity but more organ damage compared to younger patients, the incidence of serious adverse events was similar between those treated with belimumab and placebo.
- Overall, belimumab appears to be a viable treatment option for older adults with SLE, but the findings are limited due to the small sample size of older participants.
Objective: To assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE).
Methods: We performed across-study comparisons of patients with active SLE who received belimumab or placebo, plus standard therapy, in PLUTO (paediatric phase II) and BLISS-52, BLISS-76, BLISS-NEA and EMBRACE (adult phase III). Analysed efficacy data included Week 52 SLE Responder Index (SRI)-4 response rate (EMBRACE: SRI with modified Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) proteinuria scoring (SRI-S2K)); SRI-4 response rate (EMBRACE: SRI-S2K) according to baseline disease activity indicators (Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score; anti-dsDNA/C3/C4 levels); Week 52 SRI-6 response rate; and time to first severe flare (SELENA-SLEDAI Flare Index) over 52 weeks.